Serum melatonin circadian profiles in women suffering from cervical cancer

Journal of Pineal Research

Volumn 39, Issue 1, 2005, Pages 73-76

  Karasek, Michal ^a,b   Kowalski, Andrzej J ^b   Suzin, Jacek ^b   Zylinska, Krystyna ^b   Swietoslawski, Jacek ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Cervical cancer; Circadian rhythms; Malignant tumors; Metatonin; Pineal gland

Indexed keywords

MELATONIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; IMMUNOASSAY; PINEAL BODY; UTERINE CERVIX CANCER;

CIRCADIAN RHYTHM; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 22044456031     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2005.00221.x     Document Type: Article

References (25)

1. BLASK. DE. Melatonin in oncology. In: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications. Yu HS, Reiter RJ, eds. CRC Press, Boca Raton, FL, 1993; pp. 447-475.
2. KARASEK M. Relationship between the pineal gland and experimentally induced malignant tumors. Front Horm Res 1997; 23:99-106.
3. KARASEK M, PAWLIKOWSKI M. Pineal gland, melatonin and cancer. Neuroendocrinol Lett 1999; 20:139-144.
4. PAWLIKOWSKI M, WINCZYK K, KARASEK M. Oncostatic action of melatonin: facts and question marks. Neuroendocrinol Lett 2002; 23(Suppl. 1):24-29.
5. BARTSCH C, BARTSCH H, KARASEK M. Melatonin in clinical oncology. Neuroendocrinol Lett 2002; 23(Suppl. 1):30-38.
6. BARTSCH C, BARTSCH H, LAUMAS KR et al. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981; 52:281-294.
7. BARTSCH C, BARTSCH H, FUCHS U et al. Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer 1989; 64:426-433.
8. BARTSCH C, BARTSCH H, BELLMAN O et al. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991; 67:1681-1684.
9. BARTSCH C, BARTSCH H, FLÜCHTER SH et al. Circadian rhythms of serum melatonin, prolactin and growth hormone in patients with benign and malignant tumours of the prostate and in non-tumor controls. Neuroendocrinol Lett 1983; 5:377-386.
10. BARTSCH C, BARTSCH H, SCHMIDT A et al. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209:153-176.
11. KARASEK M, DEC W, KOWALSKI AJ et al. Serum melatonin circadian profile in women with adenocarcinoma of uterine corpus. Int J Thymol 1996; 4(Suppl. 1):80-83.
12. KARASEK M, KOWALSKI AJ, ZYLINSKA K. Serum melatonin circadian profile in women suffering from the genital tract cancers. Neuroendocrinol Lett 2000; 21:109-113.
13. KHOORY R, STEMME D. Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res 1988; 5:251-258.
14. KVETNAYA TV, KVETNOY IM, BARTSCH H et al. Melatonin in patients with cancer of extra-reproductive location. In: The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Bartsch C, Bartsch H, Blask DE et al., eds. Springer, Berlin, 2001; pp. 177-196.
15. FERLAY J, PARKIN DM, PISANI P. Globocan 1: Cancer Incidence and Mortality Worldwide. IARC CancerBase no. 3. IARC Press, Lyon, France, 1998.
16. DUARTE-FRANCO E, FRANCO EL. Cancer of the uterine cervix. BMC Womens Health 2004; 4(Suppl. 1):S13.
17. LISSONI P. Efficacy of melatonin in the immunotherapy of cancer using interleukin-2. In: The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Bartsch C, Bartsch H, Blask DE et al., eds. Springer, Berlin, 2001; pp. 465-475.
18. HRUSHESKY WJM. Melatonin cancer therapy. In: The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Bartsch C, Bartsch H, Blask DE et al., eds. Springer, Berlin, 2001; pp. 476-508.
19. CHEN LD, LEAL BZ, REITER RJ et al. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations. Cancer Lett 1995; 91:153-159.
20. ANISIMOV VN, ZABEZHINSKI MA, POPOVICH IG et al. Inhibitory effect of melatonin on 7,12-dimethylben[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett 2000; 156:199-205.
21. PANZER A, VILJOEN M. Urinary 6-sulfatoxymelatonin levels in osteosarcoma: a case-control study. Med Sci Res 1998; 26:43-45.
22. LISSONI P, VIVIANI S, BAJETTA E et al. A clinical study of the pineal activity in oncologic patients. Cancer 1986; 57:837-842.
23. KARASEK M, KUZDAK K, CYWINSKI J et al. Effects of melatonin administration in advanced breast cancer patients - preliminary report. Neuroendocrinol Lett 1998; 19:15-19.
24. REITER RJ, TAN DX, OSUNA C et al. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000; 7:444-458.
25. REITER RJ, TAN DX, ALLEGRA M. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuroendocrinol Lett 2002; 23(Suppl. 1):3-8.